[{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"HPAPI","year":"2021","type":"Inapplicable","leadProduct":"Apixaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Itopride Hydrochloride","moa":"DRD2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen receptor alpha","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Termination","leadProduct":"Dapagliflozin Propanediol Monohydrate","moa":"||Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ AstraZeneca"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Mebeverine","moa":"spasmolytic agents (papaverine type)","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Surmodics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Agreement","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"14-Valent Pneumococcal Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"HONG KONG","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Beta-hydroxy-beta-methylbutyrate","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Elecare","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Powder","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ensure","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Ensure Enlive","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SINGAPORE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Ensure Plus Advance","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Ensure Surgery Immunonutrition","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ivabradine Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Prolonged Release","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II\/ Phase III","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Cadrenal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Cadrenal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Tecarfarin","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Hematology","graph2":"Phase II","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Mabxience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Abbott Laboratories"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Abbott Laboratories
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
